29146-81-4

Usage

Uses

Used in Organic Synthesis:
1-(2-hydroxyethyl)thiourea is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, facilitating the creation of a wide array of organic compounds.
Used in the Production of Resins and Adhesives:
In the chemical industry, 1-(2-hydroxyethyl)thiourea is utilized as a component in the manufacturing process of certain types of resins and adhesives, contributing to their adhesive properties and performance characteristics.
Used as a Metal Complexing Agent in the Mining Industry:
1-(2-hydroxyethyl)thiourea serves as a metal complexing agent in the mining sector, where it aids in the extraction and processing of metals, enhancing the efficiency of metal recovery operations.
Used in Pharmaceutical Research:
1-(2-hydroxyethyl)thiourea has potential pharmaceutical applications, particularly in the realm of anticancer research, where it may be explored for its possible therapeutic effects against cancer cells.

Upstream product

• 29146-60-9 N-(2-hydroxyethyl)-N′-benzoylthiourea 

Downstream Products

• 113019-64-0 Ethyl 2-(2-hydroxyethylamino)-4-phenylthiazole-5-carboxylate 
• 77627-63-5 2-N-(β-hydroxyethylamino)-4-phenylthiazole 

Relevant academic research and scientific papers

Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach ?

Cystic fibrosis (CF) is a multiorgan disease caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR). In addition to respiratory impairment due to mucus accumulation, viruses and bacteria trigger acute pulmonary exacerbations, accelerating disease progression and mortality rate. Treatment complexity increases with patients' age, and simplifying the therapeutic regimen represents one of the key priorities in CF. We have recently reported the discovery of multitarget compounds able to "kill two birds with one stone" by targeting F508del-CFTR and PI4KIIIβ and thus acting simultaneously as CFTR correctors and broad-spectrum enterovirus (EV) inhibitors. Starting from these preliminary results, we report herein a hit-to-lead optimization and multidimensional structure-activity relationship (SAR) study that led to compound 23a. This compound showed good antiviral and F508del-CFTR correction potency, additivity/synergy with lumacaftor, and a promising in vitro absorption, distribution, metabolism, and excretion (ADME) profile. It was well tolerated in vivo with no sign of acute toxicity and histological alterations in key biodistribution organs.

Oxazolidone derivatives as PR modulators

Compounds of the following structure are described: wherein R1, R2, R5, R6, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

THIAZOLE DERIVATIVES AND USE THEREOF

The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.